S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.75%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.75%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.75%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.75%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

BeiGene (BGNE) Stock Price, News & Analysis

$174.54
-0.46 (-0.26%)
(As of 04:23 PM ET)
Compare
Today's Range
$171.23
▼
$174.86
50-Day Range
$158.67
▼
$201.58
52-Week Range
$156.56
▼
$280.62
Volume
248,534 shs
Average Volume
221,820 shs
Market Capitalization
$16.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$278.08
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
59.9% Upside
$278.08 Price Target
Short Interest
Bearish
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.99) to ($5.91) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

606th out of 943 stocks

Pharmaceutical Preparations Industry

278th out of 422 stocks

See Top Rated MarketRank™ Stocks Here

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

December 3, 2023 | benzinga.com
BeiGene Stock (NASDAQ:BGNE) Earnings Dates and Earning Calls
December 3, 2023 | benzinga.com
BeiGene Stock (NASDAQ:BGNE) Dividends: History, Yield and Dates
December 11, 2023 | Edge On The Street (Ad)
Is the Biden Administration Ultimately Good for Gold - and Gold Royalties?
With spending financed by deficits, increased public debt, and global uncertainty, it's no wonder many gold analysts expect prices to break all-time highs in '24. It also has investors turning to a unique "Gold Royalty" strategy offering the potential of rising gold prices without the operational risks of mining or physical gold storage.
December 3, 2023 | americanbankingnews.com
BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 23.3% in November
November 30, 2023 | finance.yahoo.com
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
November 29, 2023 | finance.yahoo.com
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 28, 2023 | finance.yahoo.com
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 23, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)
December 11, 2023 | Edge On The Street (Ad)
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
November 21, 2023 | finance.yahoo.com
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
November 21, 2023 | finance.yahoo.com
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 17, 2023 | msn.com
BeiGene's Brukinsa gets Europe approval for follicular lymphoma
November 17, 2023 | finance.yahoo.com
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 15, 2023 | finance.yahoo.com
BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd
November 14, 2023 | markets.businessinsider.com
Buy Recommendation for BeiGene: Strong Sales, Potential FDA Approval, and Improved Operating Efficiencies
November 14, 2023 | finance.yahoo.com
Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade
November 10, 2023 | finance.yahoo.com
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
November 9, 2023 | de.investing.com
BeiGene ADS: EPS übertrifft Schätzungen um 5,40 $ - Umsatz besser als erwartet
November 9, 2023 | finanznachrichten.de
BeiGene, Ltd.: BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 9, 2023 | finance.yahoo.com
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 8, 2023 | finanznachrichten.de
BeiGene, Ltd.: BeiGene to Present at the Jefferies London Healthcare Conference
November 8, 2023 | finance.yahoo.com
BeiGene to Present at the Jefferies London Healthcare Conference
November 2, 2023 | finance.yahoo.com
BeiGene, Ltd.'s (NASDAQ:BGNE) one-year returns climbed after last week's 8.9% gain, institutional investors must be happy
October 27, 2023 | businesswire.com
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in ...
October 20, 2023 | finance.yahoo.com
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 19, 2023 | msn.com
BeiGene: Staying On The Sidelines (Rating Downgrade)
October 18, 2023 | msn.com
BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
CUSIP
N/A
CIK
1651308
Web
www.beigene.com
Phone
(345) 949-4123
Fax
N/A
Employees
9,200
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$278.08
High Stock Price Target
$350.00
Low Stock Price Target
$196.00
Potential Upside/Downside
+60.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($9.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,003,810,000.00
Net Margins
-43.53%
Pretax Margin
-41.10%
Return on Equity
-23.83%
Return on Assets
-16.27%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
3.16
Quick Ratio
2.91

Sales & Book Value

Annual Sales
$1.42 billion
Price / Sales
11.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$42.17 per share
Price / Book
4.10

Miscellaneous

Outstanding Shares
95,250,000
Free Float
88,201,000
Market Cap
$16.47 billion
Optionable
Optionable
Beta
0.59

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 55)
    Co-Founder, Executive Chairman & CEO
    Comp: $2.05M
  • Dr. Xiaobin Wu Ph.D. (Age 61)
    President & COO
    Comp: $1.69M
  • Dr. Xiaodong Wang Ph.D. (Age 60)
    Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder
    Comp: $250k
  • Ms. Julia Wang (Age 52)
    CFO & Principal Accounting Officer
    Comp: $964.2k
  • Mr. Wang Lai Ph.D. (Age 46)
    Global Head of R&D
    Comp: $996.92k
  • Ms. Liza Heapes
    Head of Investor Relations
  • Mr. Chan Lee
    General Counsel & Senior VP
  • Mr. Yang Ji
    Chief Compliance Officer
  • Dr. Yan Qi
    Senior VP & Head of Public Affairs - Greater China
  • Mr. Jason W. Radford (Age 41)
    Senior Vice President of Strategy & Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BeiGene was last updated on Tuesday, November 28, 2023 at 10:26 PM.

Pros

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • BeiGene, Ltd. has a strong product portfolio that includes innovative oncology medicines such as BRUKINSA, Tislelizumab, and Pamiparib. These products have shown promising results in treating various types of cancers, providing potential for revenue growth.
  • Recent data from the Phase 3 RATIONALE 305 trial showed that Tislelizumab plus chemotherapy significantly improved overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma. This positive clinical outcome demonstrates the potential of BeiGene's products to address unmet medical needs and attract market demand.
  • BeiGene, Ltd. has established collaborations with reputable companies such as Amgen Inc., Novartis AG, and Bristol Myers Squibb company. These partnerships can provide access to additional resources, expertise, and potential market opportunities.
  • The company is actively involved in research and development, with a pipeline of potential new products targeting various solid tumors and hematological cancers. This ongoing innovation and expansion of the product pipeline can drive future growth and enhance the company's competitive position.
  • BeiGene, Ltd. is a global biotechnology company with a presence in multiple markets worldwide. This global reach provides opportunities for geographic diversification and access to a larger patient population, potentially increasing market share and revenue.

Cons

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • Investing in the biotechnology industry carries inherent risks, including the uncertainty of clinical trial outcomes, regulatory approvals, and market acceptance of new products. These risks can impact the financial performance and stock price of BeiGene, Ltd.
  • Competition in the oncology market is intense, with many established pharmaceutical companies and biotech firms developing their own cancer treatments. BeiGene, Ltd. faces competition from both large and small players, which could affect its market share and profitability.
  • The stock price of BeiGene, Ltd. is subject to market volatility and can be influenced by various factors such as overall market conditions, investor sentiment, and industry trends. Investors should carefully consider their risk tolerance and investment objectives before investing in the company.
  • The success of BeiGene, Ltd. heavily relies on the commercialization and market acceptance of its products. Any delays or setbacks in product launches, regulatory approvals, or market adoption could negatively impact the company's financial performance and investor confidence.
  • Investors should closely monitor the financial health and cash flow of BeiGene, Ltd. The company's ability to fund its research and development activities, maintain operations, and generate sustainable revenue is crucial for long-term success and shareholder value.














BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

What is BeiGene's stock price target for 2024?

12 analysts have issued 12 month target prices for BeiGene's stock. Their BGNE share price targets range from $196.00 to $350.00. On average, they expect the company's share price to reach $278.08 in the next year. This suggests a possible upside of 59.9% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2023?

BeiGene's stock was trading at $219.94 at the start of the year. Since then, BGNE shares have decreased by 21.0% and is now trading at $173.86.
View the best growth stocks for 2023 here.

Are investors shorting BeiGene?

BeiGene saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,480,000 shares, an increase of 23.3% from the October 31st total of 1,200,000 shares. Based on an average trading volume of 213,200 shares, the days-to-cover ratio is currently 6.9 days.
View BeiGene's Short Interest.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BGNE earnings forecast.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Thursday, November, 9th. The company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of ($3.38) by $5.39. The firm had revenue of $781.30 million for the quarter, compared to the consensus estimate of $596.75 million. BeiGene had a negative trailing twelve-month return on equity of 23.83% and a negative net margin of 43.53%. The business's revenue for the quarter was up 101.6% on a year-over-year basis. During the same period in the previous year, the business earned ($5.39) earnings per share.

What ETFs hold BeiGene's stock?

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), VanEck Biotech ETF (BBH), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (5.16%), Baillie Gifford & Co. (3.99%), FMR LLC (2.43%), Invesco Ltd. (1.53%), Morgan Stanley (0.15%) and Mitsubishi UFJ Trust & Banking Corp (0.11%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Bros Advisors Lp Baker, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -